ADVFN - ニュース

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

該当コードがありません。

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	21 : 00	Business Wire	Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
2024/06/01	21 : 00	GlobeNewswire Inc.	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024	NASDAQ:MOLN	Molecular Partners AG
2024/06/01	21 : 00	GlobeNewswire Inc.	CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
2024/06/01	21 : 00	Business Wire	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	NYSE:PFE	Pfizer Inc
2024/06/01	21 : 00	Business Wire	KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
2024/06/01	21 : 00	GlobeNewswire Inc.	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/06/01	21 : 00	Business Wire	Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	NYSE:PFE	Pfizer Inc
2024/06/01	21 : 00	Business Wire	Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	NASDAQ:SMMT	Summit Therapeutics Inc
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
2024/06/01	21 : 00	Business Wire	Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
2024/06/01	21 : 00	GlobeNewswire Inc.	OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	GlobeNewswire Inc.	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	NASDAQ:PPBT	Purple Biotech Ltd
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	Business Wire	Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	NYSE:TAK	Takeda Pharmaceutical Company Ltd
2024/06/01	21 : 00	GlobeNewswire Inc.	Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	NASDAQ:IMCR	Immunocore Holdings PLC
2024/06/01	21 : 00	PR Newswire (US)	Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting	NYSE:LLY	Eli Lilly and Co
2024/06/01	21 : 00	PR Newswire (US)	BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
2024/06/01	21 : 00	PR Newswire (Canada)	L'AMC souligne le Mois national de l'histoire autochtone
2024/06/01	21 : 00	PR Newswire (US)	WLR Automotive Group Celebrates Employee Philanthropy with Generous Donations
2024/06/01	21 : 00	PR Newswire (US)	Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
2024/06/01	21 : 00	PR Newswire (Canada)	CMA reflects on National Indigenous History Month
2024/06/01	21 : 00	PR Newswire (US)	New Self-Help Book Empowers LGTBQ+ People, Parents, & Allies
2024/06/01	21 : 00	PR Newswire (US)	Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
2024/06/01	21 : 00	PR Newswire (US)	James Avery Artisan Jewelry Opens New Store at Westover Marketplace
2024/06/01	21 : 00	PR Newswire (US)	TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
2024/06/01	20 : 30	Cointelegraph	Uniswap Foundation postpones vote on incentives	COIN:UNIUSD	Uniswap
2024/06/01	20 : 24	PR Newswire (Canada)	Le loyer étudiant moyen a augmenté de 20% en trois ans à Québec
2024/06/01	20 : 10	PR Newswire (US)	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

1 2 3 4 5 6 7 8 9 10 次へ >>

BNP Paribas (QX)

American Express

US Dollar vs Euro

US Dollar vs Yen

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約